Investment Thesis
VYNE faces critical financial distress with a sub-one-year cash runway ($24M cash versus $33.1M annual burn rate) despite minimal revenue generation ($570K). While the company has zero debt and improving loss metrics YoY, the combination of unsustainable operating cash burn and negligible revenue indicates urgent capital needs or potential insolvency risk without significant business inflection.
Strengths
- Zero long-term debt and minimal liabilities ($2.4M) provides flexibility
- Revenue growth of +13.8% YoY shows some commercialization traction
- Net loss improved +33.5% YoY indicating cost management efforts
- Strong liquidity position ($24M cash, 12.53x current ratio)
Risks
- Critical cash runway of approximately 9 months at current $33.1M annual burn rate
- Minimal revenue generation ($570K) despite pharmaceutical sector positioning suggests product/market fit challenges
- Massive operating cash burn (-$33.1M) exceeds revenue by 58x, indicating unsustainable business model
- Imminent capital raise required; significant equity dilution likely if needed before cash depletion
- No interest coverage and negative operating margins of -5219% indicate operational losses across all segments
Key Metrics to Watch
- Cash burn rate trajectory and quarterly runway remaining
- Revenue growth acceleration and path to breakeven operations
- Capital raise announcements and dilution impact
- Operating expense trends and cost structure optimization
- Product commercialization milestones and market adoption
Financial Metrics
Revenue
570.0K
Net Income
-26.5M
EPS (Diluted)
$-0.62
Free Cash Flow
-33.1M
Total Assets
30.2M
Cash
24.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-5,219.1%
Net Margin
-4,646.1%
ROE
-95.4%
ROA
-87.8%
FCF Margin
-5,811.2%
Balance Sheet & Liquidity
Current Ratio
12.53x
Quick Ratio
12.53x
Debt/Equity
0.00x
Debt/Assets
7.9%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-18T23:39:22.491235 |
Data as of: 2025-12-31 |
Powered by Claude AI